Home > Oncology > ASCO 2019 > Breast Cancer > ImPassion130 brings breast cancer into the immunotherapy era

ImPassion130 brings breast cancer into the immunotherapy era


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ASCO 2019
Trial
Phase 3, ImPassion130
Medical writer: Dr. Giuseppe Curigliano 2018 was a pivotal year in breast cancer research, with the phase III ImPassion130 trial bringing breast cancer into the immunotherapy era. Schmid et al.1 demonstrated a substantial overall survival (OS) benefit in patients with PD-L1–positive metastatic triple-negative breast cancer (TNBC) by the addition of the anti–PD-L1 agent atezolizumab to first-line chemotherapy with nab-paclitaxel. At median follow-up of 12.9 months, the median progression-free survival (PFS) in the ITT population was significantly improved with the addition of atezolizumab (5.5 vs. 7.2 months; HR 0.80, 95% CI [0.69, 0.92]; P = 0.002). A PFS benefit with atezolizumab was also observed in the PD-L1–positive population (5.0 vs. 7.5 months; HR 0.62, 95% CI [0.49, 0.78]; P < 0.001). An interim OS analysis was performed, and the OS difference was not statistically significant in the ITT population (median OS, 17.6 to 21.3 months; HR 0...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on